| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D237-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D237-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate |
1996-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
1999-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-H11507035-A |
| titleOfInvention |
Dihydrophthalazine antagonist of excitatory amino acid receptor |
| abstract |
(57) [Summary]nProvided are substituted dihydrophthalazine compositions that are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compositions are useful for treating disorders associated with over-activation of non-NMDA subtypes of the ionotropic EAA receptor. In addition, the compounds are useful as test agents to identify and characterize other compounds for treatment of these disorders. The compounds are useful therapeutically as analgesics or for the treatment of neuropsychiatric pharmacological disorders such as stroke, ischemia, and epilepsy. The composition can be provided in combination with a suitable carrier for oral or parenteral administration. The compounds can be administered orally or parenterally for the treatment of various disorders associated with non-NMDA EAA receptor function. |
| priorityDate |
1995-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |